Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

The initial financial outlook Intuitive Surgical management gave for 2023 was something of a letdown given the stock's high valuation.

Is Intuitive Surgical a Top Healthcare Stock to Buy for 2023?

Intuitive Surgical's (ISRG) fourth-quarter results reflect healthy demand for procedures, partially offset by lower system sales and unfavorable currency. Procedure volume in China suffers.

Intuitive Surgical (ISRG) Falls Following Q4 Earnings Miss

Alphabet

Microsoft

NVIDIA

Tesla

Artificial intelligence has been catapulted into the mainstream after the successful launch of OpenAI's ChatGPT. Andrew Rocco breaks down 5 public companies leveraging AI technology to grow their business.

The Coming AI Revolution: 5 Companies at the Forefront

A company in the health-tech space is also seeing its stock fall.

Microsoft's Not the Only Stock Pulling the Nasdaq Lower

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of -2.38% and 0%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Q4 Earnings Miss Estimates

Intuitive Surgical, Inc. (NASDAQ:ISRG ) Q4 2022 Earnings Conference Call January 24, 2023 4:30 PM ET Company Participants Brian King - Head-Investor Relations Gary Guthart - Chief Executive Officer Jamie Samath - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Rick Wise - Stifel Matt Taylor - Jefferies Anthony Petrone - Mizuho Group Shagun Singh - RBC Operator Ladies and gentlemen, good afternoon. Thank you for standing by, and welcome to the Intuitive Quarter Four 2022 Earnings Release.

Intuitive Surgical, Inc. (ISRG) Q4 2022 Earnings Call Transcript

Shares of Intuitive Surgical Inc. ISRG dropped more than 10% in the extended session Tuesday after the maker of surgical robotic systems reported fourth-quarter results slightly below Wall Street expectations and said it placed fewer of its devices during the quarter. Intuitive earned $325 million, or 91 cents a share, compared with $381 million, or $1.04 a share, in the fourth quarter of 2021.

Intuitive Surgical stock drops 10%, COVID resurgence hobbles sales

Intuitive Surgical narrowly missed fourth-quarter profit expectations on Tuesday, leading ISRG stock to dip in after-hours trading. The post Intuitive Surgical Skids As Fourth-Quarter Profit Lags Expectations appeared first on Investor's Business Daily.

Intuitive Surgical Skids As Fourth-Quarter Profit Lags Expectations

Apple

Applied Materials

ChargePoint Holdings

Marathon Digital Holdings

Palo Alto Networks

Welltower

The last three years have gone from being a market where valuation of growth stocks didn't matter to a market where investors are hesitant to buy growth stocks with exceptional valuations. So, I want to clearly explain my methodology for finding the stocks for this list.

7 Growth Stocks That Will Make You Rich in 10 Years

Advanced Micro Devices

Amazon

UiPath

Palantir Technologies

Snowflake

These high-conviction, pick-and-shovel artificial intelligence stocks can help your portfolio capture explosive gains from technology megatrends.

10 Top AI Stocks to Buy Now for the Next 10 Years

Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Intuitive Surgical (ISRG) to Post Q4 Earnings: What's in Store?

We expect Intuitive Surgical to report revenue and earnings above the street estimates, driven by a rise in total procedures volume.

Will Intuitive Surgical Stock Rise Post Q4?

Intuitive Surgical (ISRG) continues to gain traction from the increasing adoption of the da Vinci Surgical System. Improving margins buoy optimism.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

Intuitive Surgical, Inc. (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Intuitive Surgical, Inc. (ISRG) to Report a Decline in Earnings: What to Look Out for

CRISPR Therapeutics

These companies are set for a new era of growth.

2 Stocks Down More Than 25% to Buy Right Now

Chefs' Warehouse

Hims & Hers Health

OrthoPediatrics

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, including Alphabet & Intuitive Surgical

Top Wall Street analysts like these stocks amid easing inflation

Intuitive Surgical's (ISRG) revenue growth in the fourth quarter is driven by increase in procedure volume, partially offset by resurgence of COVID-19 in China.

Intuitive Surgical (ISRG) Reports Mixed Preliminary Q4 Revenues

Intuitive Surgical, Inc. is no doubt a nearly perfect company, although the investment is currently worrisome. With continued headwinds and a lofty valuation, a lot rides on what Intuitive Surgical will do with their $4 billion in cash.

Intuitive Surgical: Valuation Hanging On By The $4 Billion Cash Thread

Intuitive Surgical, Inc. (NASDAQ:ISRG ) 41st Annual J.P. Morgan Healthcare Conference Call January 11, 2023 12:00 PM ET Company Participants Gary Guthart - Chief Executive Officer Jamie Samath - Chief Financial Officer Brian Miller - Chief Digital Officer Conference Call Participants Robbie Marcus - J.P.

Intuitive Surgical, Inc. (ISRG) 41st Annual J.P. Morgan Healthcare Conference - (Transcript)

Shares of Intuitive Surgical Inc. ISRG, -4.58% sank 4.6% toward a two-month low in midday trading Wednesday, after the surgical robotics company provided a revenue outlook that was slightly below expectations, as COVID resurgences impacted procedure volumes in China. The company expects fourth-quarter revenue to rise 7% from a year ago to $1.66 billion, which is shy of the FactSet consensus of $1.69 billion.

Intuitive Surgical stocks sinks after revenue outlook comes up shy of expectations

Inmode Ltd

Intuitive Surgical disappointed Wednesday while InMode beat fourth-quarter views. But both ISRG stock and INMD stock fell in response.

Intuitive Surgical Dives As New System Rumors Flop; InMode Also Skids

SUNNYVALE, Calif., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2022 financial results ahead of its presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023.

Intuitive Announces Preliminary Fourth Quarter and Full Year 2022 Results

Medtronic

We believe Intuitive Surgical stock (NASDAQ: ISRG) is currently a better pick than Medtronic stock (NYSE: MDT), given its better prospects.

This Robotic Products Company Is A Better Pick Over Medtronic Stock

CrowdStrike

PayPal

A drubbing for growth stocks last year has created a generational buying opportunity in 2023.

3 Nasdaq 100 Stocks That Are Surefire Buys in 2023

Upstart Holdings

Don't overlook these deals in the current market.

News for Intuitive Surgical Stock (ISRG)